Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations
Daryl J Fediuk, Vaishali Sahasrabudhe, Vikas Kumar Dawra, Susan Zhou, Kevin Sweeney, Daryl J Fediuk, Vaishali Sahasrabudhe, Vikas Kumar Dawra, Susan Zhou, Kevin Sweeney
Abstract
Ertugliflozin, a sodium-glucose cotransporter 2 inhibitor, is approved for treatment of type 2 diabetes. Two population pharmacokinetic (PK) analyses were conducted, using data from up to 17 phase 1 to 3 studies, to characterize ertugliflozin PK parameters in select ethnic subgroups: (1) East/Southeast (E/SE) Asian vs non-E/SE Asian subjects; (2) Asian subjects from mainland China vs Asian subjects from the rest of the world and non-Asian subjects. A 2-compartment model with first-order absorption, lag time, and first-order elimination was fitted to the observed data. For the E/SE Asian vs non-E/SE Asian analysis (13 692 PK observations from 2276 subjects), E/SE Asian subjects exhibited a 17% increase in apparent clearance (CL/F) and 148% increase in apparent central volume of distribution (Vc/F) vs non-E/SE Asian subjects. However, individual post hoc CL/F values were similar between groups when body weight differences were considered. For the second analysis (16 018 PK observations from 2620 subjects), compared with non-Asian subjects, CL/F was similar while Vc/F increased by 44% in Asian subjects from mainland China and both CL/F and Vc/F increased in Asian subjects from the rest of the world (8% and 115%, respectively) vs non-Asian subjects. Increases in Vc/F would decrease the ertugliflozin maximum concentration but would not impact area under the concentration-time curve. Therefore, the differences in CL/F (area under the concentration-time curve) and Vc/F were not considered clinically relevant or likely to result in meaningful ethnic differences in the PK of ertugliflozin.
Trial registration: ClinicalTrials.gov NCT00989079 NCT01127308 NCT01054300 NCT01223339 NCT01948986 NCT01096667 NCT01059825 NCT01986855 NCT02033889 NCT02099110 NCT01958671 NCT02630706.
Keywords: diabetes; ertugliflozin; population pharmacokinetics; sodium-glucose cotransporter 2 inhibitor.
Conflict of interest statement
D.J.F., V.S., V.K.D., and K.S. are employees of Pfizer Inc., New York, NY, USA and may own shares/stock options in Pfizer Inc. S.Z. is an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and may own stock in Merck & Co., Inc., Kenilworth, NJ, USA.
© 2021 Merck Sharp & Dohme Corp and Pifzer Inc. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Figures
References
- International Diabetes Federation . IDF Diabetes Atlas, 9th ed. Brussels, Belgium. . Published 2019. Accessed December 18, 2020.
- Abdul‐Ghani MA, Norton L, DeFronzo RA. Renal sodium‐glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol. 2015;309(11):F889‐F900.
- Kalgutkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF‐04971729, a selective inhibitor of the sodium‐dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011;39(9):1609‐1619.
- Miao Z, Nucci G, Amin N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF‐04971729) in healthy male subjects. Drug Metab Dispos. 2013;41(2):445‐456.
- Dagogo‐Jack S, Liu J, Eldor R, et al. Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study. Diabetes Obes Metab. 2018;20(3):530‐540.
- Grunberger G, Camp S, Johnson J, et al. Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: the VERTIS RENAL randomized study. Diabetes Ther. 2018;9(1):49‐66.
- Hollander P, Liu J, Hill J, et al. Ertugliflozin compared with glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin: the VERTIS SU randomized study. Diabetes Ther. 2018;9(1):193‐207.
- Ji L, Liu Y, Miao H, et al. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes Metab. 2019;21(6):1474‐1482.
- Miller S, Krumins T, Zhou H, et al. Ertugliflozin and sitagliptin co‐initiation in patients with type 2 diabetes: the VERTIS SITA randomized study. Diabetes Ther. 2018;9(1):253‐268.
- Pratley RE, Eldor R, Raji A, et al. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: the VERTIS FACTORIAL randomized trial. Diabetes Obes Metab. 2018;20(5):1111‐1120.
- Terra SG, Focht K, Davies M, et al. Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone. Diabetes Obes Metab. 2017;19(5):721‐728.
- Raje S, Callegari E, Sahasrabudhe V, et al. Novel application of the two‐period microtracer approach to determine absolute oral bioavailability and fraction absorbed of ertugliflozin. Clin Transl Sci. 2018;11(4):405‐411.
- Fediuk DJ, Nucci G, Dawra VK, et al. Overview of the clinical pharmacology of ertugliflozin, a novel sodium‐glucose cotransporter 2 (SGLT2) inhibitor. Clin Pharmacokinet. 2020;59(8):949‐965.
- Sahasrabudhe V, Fediuk DJ, Matschke K, et al. Effect of food on the pharmacokinetics of ertugliflozin and its fixed‐dose combinations ertugliflozin/sitagliptin and ertugliflozin/metformin. Clin Pharmacol Drug Dev. 2019;8(5):619‐627.
- Nucci G, Le V, Sweeney K, Amin N. Single‐ and multiple‐dose pharmacokinetics and pharmacodynamics of ertugliflozin, an oral selective inhibitor of SGLT2, in healthy subjects. Clin Pharmacol Ther. 2018;103(S1):S83.
- Dawra VK, Liang Y, Shi H, et al. A PK/PD study comparing twice‐daily to once‐daily dosing regimens of ertugliflozin in healthy subjects. Int J Clin Pharmacol Ther. 2019;57(4):207‐216.
- Sahasrabudhe V, Terra SG, Hickman A, et al. The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2017;57(11):1432‐1443.
- Dawra VK, Cutler DL, Zhou S, et al. Assessment of the drug interaction potential of ertugliflozin with sitagliptin, metformin, glimepiride, or simvastatin in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(3):314‐325.
- Liang Y, Sahasrabudhe V, Tensfeldt T, et al. Meta‐analysis of non‐compartmental pharmacokinetic parameters of ertugliflozin to evaluate dose proportionality and effect of UGT1A9 polymorphism on exposure [published online ahead of print April 4, 2021]. J Clin Pharm. 10.1002/jcph.1866.
- Li Y, Mu Y, Shi H, et al. Pharmacokinetic properties of single and multiple doses of ertugliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects. Clin Pharmacol Drug Dev. 2020;9(1):97‐106.
- Li Y, Nucci G, Yamamoto Y, Sahasrabudhe V, DJ F. Pharmacokinetics and pharmacodynamics of ertugliflozin in healthy Japanese and Western subjects [published online ahead of print January 12, 2021]. Clin Pharmacol Drug Dev. 10.1002/cpdd.908.
- Fediuk DJ, Zhou S, Dawra VK, Sahasrabudhe V, Sweeney K. Population pharmacokinetic model for ertugliflozin in healthy subjects and patients with type 2 diabetes mellitus [published online ahead of print November 17, 2020]. Clin Pharmacol Drug Dev. 10.1002/cpdd.885.
- Liu J, Patel S, Cater NB, et al. Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2020;22(4):574‐582.
- Sahasrabudhe V, Terra SG, Hickman A, et al. Pharmacokinetics of single‐dose ertugliflozin in patients with hepatic impairment. Clin Ther. 2018;40(10):1701‐1710.
- Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129‐2140.
- Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281:64‐91.
- Yabe D, Yasui A, Ji L, et al. Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: pooled analysis of phase I‐III clinical trials. J Diabetes Investig. 2019;10(2):418‐428.
- Ji L, Han P, Liu Y, et al. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea. Diabetes Obes Metab. 2015;17(1):23‐31.
- European Medicines Agency . ICH Topic E 5 (R1) Ethnic Factors in the Acceptability of Foreign Clinical Data. Amsterdam: European Medicines Agency; 1998.
- Liu J, Tarasenko L, Pong A, et al. Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020;36(8):1277‐1284.
- Liu J, Tarasenko L, Pong A, et al. Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus. Curr Med Res Opin. 2020;36(7):1097‐1106.
- Hwang MS, Lee SJ, Jeong HE, Lee S, Yoo MA, Shin JG. Genetic variations in UDP‐glucuronosyltransferase 2B7 gene (UGT2B7) in a Korean population. Drug Metab Pharmacokinet. 2010;25(4):398‐402.
Source: PubMed